Thus, BRCA1 and RAD51C promoter methylation, likely in combination with LOH, may have led to the HRD phenotype for a sizable portion of the ovarian and of breast cancer patients with no clear biallelic loss of the HRD associated genes, and potentially for patients with other cancer types as well (Supplementary Fig. 23). This evidence concerns the gene RAD51C and breast carcinoma.